Fluvastatin suppresses mast cell and basophil IgE responses: Genotype-dependent effects

Elizabeth Motunrayo Kolawole; Jamie Josephine Avila McLeod; Victor Ndaw; Daniel Abebayehu; Brian O. Barnstein; Travis Faber; Andrew J. Spence; Marcela Taruselli; Anuya Paranjape; Tamara T. Haque; Amina A. Qayum; Qasim A. Kazmi; Dayanjan S. Wijesinghe; Jamie L. Sturgill; Charles E. Chalfant; David B. Straus; Carole A. Oskeritzian; John J. Ryan

doi:10.4049/jimmunol.1501932

Fluvastatin suppresses mast cell and basophil IgE responses: Genotype-dependent effects

Elizabeth Motunrayo Kolawole, Jamie Josephine Avila McLeod, Victor Ndaw, Daniel Abebayehu, Brian O. Barnstein, Travis Faber, Andrew J. Spence, Marcela Taruselli, Anuya Paranjape, Tamara T. Haque, Amina A. Qayum, Qasim A. Kazmi, Dayanjan S. Wijesinghe, Jamie L. Sturgill, Charles E. Chalfant, David B. Straus, Carole A. Oskeritzian, John J. Ryan

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

Mast cell (MC)-and basophil-associated inflammatory diseases are a considerable burden to society. A significant portion of patients have symptoms despite standard-of-care therapy. Statins, used to lower serum cholesterol, have immune-modulating activities. We tested the in vitro and in vivo effects of statins on IgE-mediated MC and basophil activation. Fluvastatin showed the most significant inhibitory effects of the six statins tested, suppressing IgE-induced cytokine secretion among mouse MCs and basophils. The effects of fluvastatin were reversed by mevalonic acid or geranylgeranyl pyrophosphatase, and mimicked by geranylgeranyl transferase inhibition. Fluvastatin selectively suppressed key FcRI signaling pathways, including Akt and ERK. Although MCs and basophils from the C57BL/6J mouse strain were responsive to fluvastatin, those from 129/SvImJ mice were completely resistant. Resistance correlated with fluvastatin-induced upregulation of the statin target HMG-CoA reductase. Human MC cultures from eight donors showed a wide range of fluvastatin responsiveness. These data demonstrate that fluvastatin is a potent suppressor of IgE-mediated MC activation, acting at least partly via blockade of geranyl lipid production downstream of HMG-CoA reductase. Importantly, consideration of statin use for treating MC-associated disease needs to incorporate genetic background effects, which can yield drug resistance.

Original language	English
Pages (from-to)	1461-1470
Number of pages	10
Journal	Journal of Immunology
Volume	196
Issue number	4
DOIs	https://doi.org/10.4049/jimmunol.1501932
State	Published - Feb 15 2016

Bibliographical note

Funding Information:
We thank Dr. Daniel Conrad for many helpful conversations concerning this manuscript. This work was supported by the National Institutes of Health (Grants 1R01AI101153 and 2R01AI059638 to J.J.R.; Grant 1R01 AI095494 to C.A.O.; Grants HL125353 and CA154314 to C.E.C.; and Grant NH1C06-RR17393 to Virginia Commonwealth University for renovation) and by the Veteran’s Administration (VA Merit Review I BX001792 and Research Career Scientist Award 1 3F-RCS-002 to C.E.C.). Services (VCU Lipidomics/Metabolomics Core Facility) and products in support of the research project were generated in part by the VCU Massey Cancer Center (shared and supported) with funding from National Institutes of Health-National Cancer Institute Cancer Center Support Grant P30 CA016059.

Publisher Copyright:
Copyright © 2016 by The American Association of Immunologists, Inc.

ASJC Scopus subject areas

Immunology and Allergy
Immunology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.4049/jimmunol.1501932

Cite this

Kolawole, E. M., McLeod, J. J. A., Ndaw, V., Abebayehu, D., Barnstein, B. O., Faber, T., Spence, A. J., Taruselli, M., Paranjape, A., Haque, T. T., Qayum, A. A., Kazmi, Q. A., Wijesinghe, D. S., Sturgill, J. L., Chalfant, C. E., Straus, D. B., Oskeritzian, C. A., & Ryan, J. J. (2016). Fluvastatin suppresses mast cell and basophil IgE responses: Genotype-dependent effects. Journal of Immunology, 196(4), 1461-1470. https://doi.org/10.4049/jimmunol.1501932

@article{31252e3c127c45b4b34bc16c430ac763,

title = "Fluvastatin suppresses mast cell and basophil IgE responses: Genotype-dependent effects",

abstract = "Mast cell (MC)-and basophil-associated inflammatory diseases are a considerable burden to society. A significant portion of patients have symptoms despite standard-of-care therapy. Statins, used to lower serum cholesterol, have immune-modulating activities. We tested the in vitro and in vivo effects of statins on IgE-mediated MC and basophil activation. Fluvastatin showed the most significant inhibitory effects of the six statins tested, suppressing IgE-induced cytokine secretion among mouse MCs and basophils. The effects of fluvastatin were reversed by mevalonic acid or geranylgeranyl pyrophosphatase, and mimicked by geranylgeranyl transferase inhibition. Fluvastatin selectively suppressed key FcRI signaling pathways, including Akt and ERK. Although MCs and basophils from the C57BL/6J mouse strain were responsive to fluvastatin, those from 129/SvImJ mice were completely resistant. Resistance correlated with fluvastatin-induced upregulation of the statin target HMG-CoA reductase. Human MC cultures from eight donors showed a wide range of fluvastatin responsiveness. These data demonstrate that fluvastatin is a potent suppressor of IgE-mediated MC activation, acting at least partly via blockade of geranyl lipid production downstream of HMG-CoA reductase. Importantly, consideration of statin use for treating MC-associated disease needs to incorporate genetic background effects, which can yield drug resistance.",

author = "Kolawole, {Elizabeth Motunrayo} and McLeod, {Jamie Josephine Avila} and Victor Ndaw and Daniel Abebayehu and Barnstein, {Brian O.} and Travis Faber and Spence, {Andrew J.} and Marcela Taruselli and Anuya Paranjape and Haque, {Tamara T.} and Qayum, {Amina A.} and Kazmi, {Qasim A.} and Wijesinghe, {Dayanjan S.} and Sturgill, {Jamie L.} and Chalfant, {Charles E.} and Straus, {David B.} and Oskeritzian, {Carole A.} and Ryan, {John J.}",

note = "Funding Information: We thank Dr. Daniel Conrad for many helpful conversations concerning this manuscript. This work was supported by the National Institutes of Health (Grants 1R01AI101153 and 2R01AI059638 to J.J.R.; Grant 1R01 AI095494 to C.A.O.; Grants HL125353 and CA154314 to C.E.C.; and Grant NH1C06-RR17393 to Virginia Commonwealth University for renovation) and by the Veteran{\textquoteright}s Administration (VA Merit Review I BX001792 and Research Career Scientist Award 1 3F-RCS-002 to C.E.C.). Services (VCU Lipidomics/Metabolomics Core Facility) and products in support of the research project were generated in part by the VCU Massey Cancer Center (shared and supported) with funding from National Institutes of Health-National Cancer Institute Cancer Center Support Grant P30 CA016059. Publisher Copyright: Copyright {\textcopyright} 2016 by The American Association of Immunologists, Inc.",

year = "2016",

month = feb,

day = "15",

doi = "10.4049/jimmunol.1501932",

language = "English",

volume = "196",

pages = "1461--1470",

number = "4",

}

Kolawole, EM, McLeod, JJA, Ndaw, V, Abebayehu, D, Barnstein, BO, Faber, T, Spence, AJ, Taruselli, M, Paranjape, A, Haque, TT, Qayum, AA, Kazmi, QA, Wijesinghe, DS, Sturgill, JL, Chalfant, CE, Straus, DB, Oskeritzian, CA & Ryan, JJ 2016, 'Fluvastatin suppresses mast cell and basophil IgE responses: Genotype-dependent effects', Journal of Immunology, vol. 196, no. 4, pp. 1461-1470. https://doi.org/10.4049/jimmunol.1501932

TY - JOUR

T1 - Fluvastatin suppresses mast cell and basophil IgE responses

T2 - Genotype-dependent effects

AU - Kolawole, Elizabeth Motunrayo

AU - McLeod, Jamie Josephine Avila

AU - Ndaw, Victor

AU - Abebayehu, Daniel

AU - Barnstein, Brian O.

AU - Faber, Travis

AU - Spence, Andrew J.

AU - Taruselli, Marcela

AU - Paranjape, Anuya

AU - Haque, Tamara T.

AU - Qayum, Amina A.

AU - Kazmi, Qasim A.

AU - Wijesinghe, Dayanjan S.

AU - Sturgill, Jamie L.

AU - Chalfant, Charles E.

AU - Straus, David B.

AU - Oskeritzian, Carole A.

AU - Ryan, John J.

N1 - Funding Information: We thank Dr. Daniel Conrad for many helpful conversations concerning this manuscript. This work was supported by the National Institutes of Health (Grants 1R01AI101153 and 2R01AI059638 to J.J.R.; Grant 1R01 AI095494 to C.A.O.; Grants HL125353 and CA154314 to C.E.C.; and Grant NH1C06-RR17393 to Virginia Commonwealth University for renovation) and by the Veteran’s Administration (VA Merit Review I BX001792 and Research Career Scientist Award 1 3F-RCS-002 to C.E.C.). Services (VCU Lipidomics/Metabolomics Core Facility) and products in support of the research project were generated in part by the VCU Massey Cancer Center (shared and supported) with funding from National Institutes of Health-National Cancer Institute Cancer Center Support Grant P30 CA016059. Publisher Copyright: Copyright © 2016 by The American Association of Immunologists, Inc.

PY - 2016/2/15

Y1 - 2016/2/15

N2 - Mast cell (MC)-and basophil-associated inflammatory diseases are a considerable burden to society. A significant portion of patients have symptoms despite standard-of-care therapy. Statins, used to lower serum cholesterol, have immune-modulating activities. We tested the in vitro and in vivo effects of statins on IgE-mediated MC and basophil activation. Fluvastatin showed the most significant inhibitory effects of the six statins tested, suppressing IgE-induced cytokine secretion among mouse MCs and basophils. The effects of fluvastatin were reversed by mevalonic acid or geranylgeranyl pyrophosphatase, and mimicked by geranylgeranyl transferase inhibition. Fluvastatin selectively suppressed key FcRI signaling pathways, including Akt and ERK. Although MCs and basophils from the C57BL/6J mouse strain were responsive to fluvastatin, those from 129/SvImJ mice were completely resistant. Resistance correlated with fluvastatin-induced upregulation of the statin target HMG-CoA reductase. Human MC cultures from eight donors showed a wide range of fluvastatin responsiveness. These data demonstrate that fluvastatin is a potent suppressor of IgE-mediated MC activation, acting at least partly via blockade of geranyl lipid production downstream of HMG-CoA reductase. Importantly, consideration of statin use for treating MC-associated disease needs to incorporate genetic background effects, which can yield drug resistance.

AB - Mast cell (MC)-and basophil-associated inflammatory diseases are a considerable burden to society. A significant portion of patients have symptoms despite standard-of-care therapy. Statins, used to lower serum cholesterol, have immune-modulating activities. We tested the in vitro and in vivo effects of statins on IgE-mediated MC and basophil activation. Fluvastatin showed the most significant inhibitory effects of the six statins tested, suppressing IgE-induced cytokine secretion among mouse MCs and basophils. The effects of fluvastatin were reversed by mevalonic acid or geranylgeranyl pyrophosphatase, and mimicked by geranylgeranyl transferase inhibition. Fluvastatin selectively suppressed key FcRI signaling pathways, including Akt and ERK. Although MCs and basophils from the C57BL/6J mouse strain were responsive to fluvastatin, those from 129/SvImJ mice were completely resistant. Resistance correlated with fluvastatin-induced upregulation of the statin target HMG-CoA reductase. Human MC cultures from eight donors showed a wide range of fluvastatin responsiveness. These data demonstrate that fluvastatin is a potent suppressor of IgE-mediated MC activation, acting at least partly via blockade of geranyl lipid production downstream of HMG-CoA reductase. Importantly, consideration of statin use for treating MC-associated disease needs to incorporate genetic background effects, which can yield drug resistance.

UR - http://www.scopus.com/inward/record.url?scp=84958568998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958568998&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1501932

DO - 10.4049/jimmunol.1501932

M3 - Article

C2 - 26773154

AN - SCOPUS:84958568998

SN - 0022-1767

VL - 196

SP - 1461

EP - 1470

JO - Journal of Immunology

JF - Journal of Immunology

IS - 4

ER -

Fluvastatin suppresses mast cell and basophil IgE responses: Genotype-dependent effects

Abstract

Bibliographical note

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this